Depressive Disorder

Oct 03, 2019

Neuronetics® Unveils Promising New Depression Research Data at Psych Congress

Oct 02, 2019

Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent

Aug 19, 2019

Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium

Jan 24, 2019

Global Major Depressive Disorder (MDD) Market Insights, Epidemiology and Market Forecasts, 2016-2027

May 03, 2018

Janssen to Present Data in Treatment-Resistant Depression, Schizophrenia, Health Economics and Outcomes and Population Health at American Psychiatric Association 2018 Meeting

May 02, 2018

TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)

Apr 16, 2018

Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality

Aug 02, 2017

23andMe Begins Enrollment for First-of-its-Kind Study on Major Depressive and Bipolar Disorders